KCI, LifeCell and Systagenix Combine Into One “Transformational Healing Solutions” Company

KCI is bringing together recently acquired Systagenix and LifeCell to form what it calls one “globally diversified wound care, biologics and regenerative medicine company”.

Background

Back in July we announced KCI’s acquisition of J&J spin-off, Systagenix. This follows the 2008 acquisition of LifeCell Corporation. Now it’s been announced that once the Systagenix acquisition closes, the three business will be organised into one company under the leadership of KCI President & CEO Joe Woody.

In a press release, KCI lays out modest claims for the combined company, saying it will be the “global leader in transformational healing solutions, devoted to advancing the science of healing with superior products, innovative therapies and cost effective solutions that speed healing, reduce complications and improve patient lives”.

Not being one to hide its light under a bushel, KCI’s release follows up with; “as one of the top global medical technology companies, the combined company will remain the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair and a market leader in advanced wound care”.

Company comments

“The combination of these businesses will form a leading medical technology company with over $2 billion in revenue and a very important position within the healthcare system,” said Buddy Gumina, chairman of the Board of Directors of the parent company of KCI and LifeCell. “The new company, under the proven leadership of Joe Woody, will amplify existing capabilities, open the door for new growth opportunities and improve the lives of patients around the world.”

“Operating as one company will foster collaboration and increased innovation across platforms, leading to exciting new products that will address unmet clinical needs,” said Joe Woody, president & CEO. “The combination of KCI, LifeCell and Systagenix will allow us to strengthen our customer relationships, while creating opportunities to cross-sell our products across the entire continuum of care – following the patient from the operating room to the home with a combined portfolio of best-in-class products and therapies.”

Source: Kinetic Concepts, Inc., Business wire